Altimmune, Inc.
ALT
$4.07
$0.071.75%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 0.00% | 0.00% | -86.49% | -98.62% | -16.67% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 0.00% | 0.00% | -86.49% | -98.62% | -16.67% |
| Cost of Revenue | -18.53% | -26.34% | 16.99% | 7.70% | 59.62% |
| Gross Profit | 18.53% | 26.35% | -17.21% | -9.83% | -59.66% |
| SG&A Expenses | 1.72% | 12.82% | 17.50% | 10.08% | 17.54% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -14.29% | -18.58% | 17.09% | 8.17% | 48.50% |
| Operating Income | 14.29% | 18.58% | -17.27% | -9.88% | -48.53% |
| Income Before Tax | 10.12% | 16.96% | 26.74% | -10.52% | -53.42% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 10.12% | 19.75% | 26.74% | -10.52% | -53.42% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 10.12% | 19.75% | 26.74% | -10.52% | -53.42% |
| EBIT | 14.29% | 18.58% | -17.27% | -9.88% | -48.53% |
| EBITDA | 14.21% | 18.36% | -17.75% | -10.31% | -49.22% |
| EPS Basic | 21.76% | 24.79% | 39.92% | 16.61% | -9.66% |
| Normalized Basic EPS | 21.74% | 22.16% | 1.12% | 16.60% | -9.65% |
| EPS Diluted | 21.76% | 24.79% | 39.92% | 16.61% | -9.66% |
| Normalized Diluted EPS | 21.74% | 22.16% | 1.12% | 16.60% | -9.65% |
| Average Basic Shares Outstanding | 14.88% | 6.70% | 21.93% | 32.54% | 39.91% |
| Average Diluted Shares Outstanding | 14.88% | 6.70% | 21.93% | 32.54% | 39.91% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |